The scientific results from intratumoral injections with Liproca® Depot as confirmed by Magnetic Resonance Imaging and Spectroscopy, have been accepted for presentation at the International Society for Magnetic Resonance in Medicine (ISMRM) in Paris in June 2018. The spectroscopy demonstrates metabolic atrophy and antitumor effects from Liproca® Depot.
The overall results from the Phase II clinical studies, LPC-002 and LPC-003, on Liproca Depot, which confirmed PSA and prostate volume reductions without hormonal side effects after intraprostatic injections, were published in the American publication The Journal of Urology in December 2016. The now accepted presentation focuses on clinical anticancer effects as observed with modern magnetic resonance spectroscopy (MRS) techniques. The results demonstrate the power of MRS techniques to detect metabolic atrophy and anti-tumor affects already after six weeks local treatment with hormone-deprivation therapy with Liproca Depot.
For more information, please contact:
Monica Wallter, CEO LIDDS, +46 (0)737 07 09 22, monica.wallter@liddspharma.com
LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through the agency of the aforementioned contact person for publication on 8 February 2018 at 08.30 CET.
About LIDDS
LIDDS AB (publ) develops effective medications for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and efficiently, which means significantly fewer side effects and treatments compared with systemic treatment. NanoZolid technology allows for the controlled, long-term and adjusted release of the medication for up to six months. NanoZolid can be combined with both large and small pharmaceutical molecules. The company's most advanced project is the prostate cancer product Liproca® Depot, which contains 2-hydroxyflutamide, which confirms that the technology has a documented clinical effect. The prostate cancer project is currently in Phase IIb. Industrial-scale production is taking place in collaboration with Recipharm. LIDDS has active development projects where NanoZolid is combined with antiandrogens, cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North. Redeye AB is a certified adviser to LIDDS. For more information, go to liddspharma.com.
—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LIDDS AB via Globenewswire